Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Medivation Inc    MDVN   US58501N1019


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

10/30/2013 | 04:34pm US/Eastern

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting:

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
Latest news on MEDIVATION INC
13h ago ASTELLAS PHARMA : Announces Revision of Package Insert in Japan for XTANDI (enza..
5d ago MEDIVATION : Change in Directors or Principal Officers (form 8-K)
10/09 MEDIVATION : EY : Announces leaders from Medivation, MongoDB, Trulia, and zulily..
09/23 MEDIVATION : and Astellas Pharma: FDA Grants Approval for New Xtandi Indication
09/17 ASTELLAS PHARMA : U.S. FDA Approves New Indication for the Use of XTANDI® enzalu..
09/16 MEDIVATION : FDA Grants Approval to New Xtandi Indication
09/15 ASTELLAS PHARMA : FDA Oks New Indication for the Use of XTANDI (enzalutamide) Ca..
09/15 ASTELLAS PHARMA : FDA Approves New Indication for the Use of XTANDI (enzalutamid..
09/11 MEDIVATION : ASTELLAS -U.S. FDA Approves New Indication for the Use of XTANDI (e..
09/10 MEDIVATION : U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutami..
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes